Ambient Fine Particulate Matter Exposure and Myocardial Ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women’s Health Initiative (EEAWHI) Study

Zhu-ming Zhang,1 Eric A. Whitsel,2,3 P. Miguel Quibrala,2 Richard L. Smith,4 Duaping Liao,5 Garnet L. Anderson,6 and Ronald J. Prineas1

1Epidemiologic Cardiology Research Center, Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; 2Departments of Epidemiology, 3Medicine, and 4Statistics and Operations Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 5Department of Health Evaluation Sciences, Pennsylvania State University, Hershey, Pennsylvania, USA; 6Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

BACKGROUND: Ambient particulate matter (PM) air pollution is associated with coronary heart disease, but the pathways underlying the association remain to be elucidated.

METHODS: We studied the association between PM and ischemia among 57,908 Women’s Health Initiative clinical trial participants from 1999–2003. We used the Minnesota Code criteria to identify ST-segment and T-wave abnormalities, and estimated T amplitude (microvolt) from resting, standard 12-lead electrocardiogram (ECG). We used U.S. Environmental Protection Agency’s monitor data to estimate concentrations of PM < 2.5 µm (PM2.5) at geocoded participant addresses over 6 days before the ECGs (lag0 through lag5). We excluded 2,379 women with ECG QRS duration ≥ 120 msec.

RESULTS: Overall, 6% of the remaining 55,529 women (52–90 years of age; 83% non-Hispanic white) had ST abnormalities and 16% had T abnormalities. Lead-specific T amplitude was normally distributed (range of means from –14 to 349 µV). PM2.5 (mean ± SD) associated with a 2.5% (95% confidence interval [CI], –3% to 10%) increase in the odds of ST abnormality and a 5% (95% CI, 0% to 9%) increase in the odds of T abnormality. We observed corresponding decreases in T amplitude in all exam sites and leads except lead V1, reaching a minimum of –2 µV (95% CI, –5 to 0 µV) in lead V3.

CONCLUSIONS: Short-term PM2.5 exposure is associated with ECG evidence of myocardial ischemia among postmenopausal women. The principal manifestations include subclinical but potentially arrhythmogenic ST–T abnormalities and decreases in T amplitude.

KEY WORDS: air pollution, cardiovascular disease, electrocardiography, myocardial ischemia, particulate matter. Environ Health Perspect 117:751–756 (2009). doi:10.1289/ehp.0800046 available via http://dx.doi.org/ [Online 23 January 2009]

Studies of human populations show that ambient particulate matter (PM) air pollution is associated with coronary heart disease (CHD) morbidity and mortality. The consistent findings suggest direct associations between both short- and long-term exposure to PM and CHD incident [Brook et al. 2004; Dockery et al. 1993; Miller et al. 2007; Pope et al. 2006; U.S. Environmental Protection Agency (EPA) 2006]. However, biological mechanisms underlying the association between PM and CHD remain incompletely characterized in human populations despite calls for epidemiologic research designed to help elucidate them [Brook et al. 2004; Health Effects Institute 2002; National Research Council 2004].

Resting, supine, standard 12-lead electrocardiography (ECC) has been recognized as a potentially valuable epidemiologic tool in this regard, yet to date much of its value remains unrealized. ECC findings characteristic of myocardial ischemia, for example, have not been adequately evaluated in this context. These measures include ST-segment depression and T-wave inversion on the ECG.

Because of their clinical value, these ECC findings have also attracted environmental, toxicologic, and epidemiologic interest. Indeed, they are thought to be relevant in studies focusing on arrhythmogenic effects of air pollution [Zareba et al. 2001] and risk factors for sudden death due to cardiac arrhythmia (Huikuri et al. 2001). The literature in this area has nevertheless focused on experimentation in animal models of coronary vasoconstriction (Campen et al. 2005; Godleski et al. 2000; Nikolov et al. 2007; Wellenius et al. 2003) or examination of typically small, single-city panels of CHD-burdened, Holter-monitored male participants during exercise (Gold et al. 2005; Henneberger et al. 2005; Lanki et al. 2006; Mills et al. 2007; Pekkanen et al. 2002; Yue et al. 2007). For this reason, epidemiologic evidence linking PM exposure to minor but prognostically important abnormalities of the ST segment and T wave in human populations at rest is quite limited.

We therefore designed the present study to investigate the association between acute exposures to ambient PM < 2.5 µm in diameter (PM2.5) and ECC measures of myocardial ischemia in a relatively large, spatially diverse, healthy female population enrolled in the Women’s Health Initiative (WHI) clinical trials.

Methods

Study design. We examined the association between PM2.5 and ischemia in the Environmental Epidemiology of Arrhythmogenesis in WHI (EEAWHI) study, an ancillary study of proarrhythmic mechanisms linking air pollution and CHD among 68,133 WHI clinical trial participants examined at 49 sites. The WHI clinical trial is a multi-center study of risk factors for prevention of common causes of mortality, morbidity, and impaired quality of life in U.S. postmenopausal women. Details of the study design, including recruitment procedures and selection and exclusion criteria, have been published elsewhere (WHI Study Group 1998). The study was approved by each study site’s institutional review board. All participants provided written informed consent.

Study population. Of the 68,133 WHI clinical trial participants at baseline, we excluded 2,082 (3.1%) with foreign, U.S. military, U.S. protectorate, Hawaiian, Alaskan, or missing addresses; 417 (0.6%) with missing or poor-quality ECGs; 2,379 (3.5%) with ECC QRS duration ≥ 120 msec; and 7,726 (11%)
without an ECG recording between 1999 and 2003, the initial 5-year period in which PM2.5 data were routinely collected by the U.S. EPA Air Quality System (AQS). The present study focuses on the initial high-quality, resting, standard 12-lead ECGs recorded during this period among the remaining 55,529 participants, all of whom had addresses in the contiguous United States.

**ECG methodology.** Identical ECGs (MAC PC, Marquette Electronics, Inc., Milwaukee, WI) were used in all clinic sites, and resting, standard 12-lead ECGs were recorded for all participants using strictly standardized procedures. The chest electrodes were located in precise positions. All ECGs were processed in a central ECG laboratory (Epidemiological Cardiology Research Center, Wake Forest University, Winston-Salem, NC), where they were visually inspected for technical errors and inadequate quality. The ECGs were initially processed with the Dalhousie ECG program, and for the present study we reprocessed them with the 2001 version of the GE Marquette 12-lead program (GE Healthcare 2008; Prineas et al. 1982; Rautaharju et al. 1998). The Marquette measurement matrix contained several ECG measures of myocardial ischemia that we used as outcome variables in this study.

**ST-segment and T-wave amplitudes (microvolt).** We defined lead-specific depth (or height) of the ST segment (ST) 60 msec after the J point and T-wave amplitude (T) relative to the isoelectric line.

**ST, T, and ST–T abnormalities.** We applied Minnesota codes (MC) criteria to the former interval-scale measures to identify ST abnormality (MC 4.1–4.4), T abnormality (MC 5.1–5.4), or any ST–T abnormality (MC 4.1–4.4 or MC 5.1–5.4) (Prineas et al. 1982).

**QRS/T angles (degrees).** The frontal plane QRS/T angle was defined as the absolute value of the difference between the frontal plane QRS and T axes (range, $-89^\circ$ to $270^\circ$).

When $>180^\circ$, it was adjusted to the minimal angle as follows: $360^\circ$ – frontal plane QRS/T angle (Zhang et al. 2007). We defined the spatial QRS/T angle as the angle between the mean QRS and T vectors, which we calculated from quasi-orthogonal X, Y, and Z leads reconstructed from the standard ECG leads via matrix transformation (Rautaharju et al. 2006).

**Air pollutant concentrations, weather variables, and other participant characteristics.** We obtained all ambient PM2.5 concentration data recorded at monitors operating in the contiguous United States during the study from the U.S. EPA AQS. The data included the longitude and latitude of each monitor.

We used a semiautomated program built on ArcView GIS (version 8.3) software and its Geostatistical Analyst extension (ESRI, Inc. Redlands, CA) to produce kriging-estimated daily mean concentrations (and their SEs) at each geocoded participant and exam site address from baseline to closeout were estimated by averaging within overlapping 1-, 2-, and 3-day lag combinations inside a 6-day exposure window beginning 5 days before and ending on the examination date, that is, days 0–5. Associations between PM and ischemia were strongest on days 0–2 ($\text{lag}_0.2$), the emphasis of the present report.

We obtained all meteorologic data recorded at relevant stations and times from the National Climatic Data Center (U.S. National Climatic Data Center 2007); ambient temperature (degrees centigrade), dew point (degrees centigrade), and barometric pressures (kilo pascal), as well as station longitudes, latitudes, and altitudes. Daily mean temperature, dew point, and pressure at each geocoded participant and exam site address from baseline to closeout were estimated by averaging daily means across all stations within 50 km, a distance over which their station-to-station correlations exceed 0.90 (Ito et al. 2001). Thereafter, we computed weather variables at $\text{lag}_0.2$/$\text{lag}_1.5$ as described above for PM2.5.

Self-reported education, medication use, health history, and a variety of other attributes were determined at each visit by standardized participant interview and examination by the WHI staff. Interim health events were identified via standardized medical record review and physician adjudication. Specifically, diabetics was defined by antidiabetic medication use or history; hypertension by antihypertensive medication use, systolic blood pressure (SBP) $\geq 140$ mmHg, diastolic blood pressure (DBP) $\geq 90$ mmHg, or history; body mass index (BMI) as the ratio of weight (kilograms) to height (square meters); hypercholesterolemia by antihyperlipidemic medication use or history; smoking as current, former, or never; chronic lung disease by history of asthma, emphysema, or lung cancer; CHD by antianginal medication use, history of angina, or myocardial infarction and medical record review/adjudication; revascularization by history of coronary artery angioplasty, stent, or bypass and medical record review/adjudication; and congestive heart failure by cardiac glycoside/diuretic use, history, and medical record review/adjudication.

**Statistical analysis methods.** We inspected frequency distributions of all variables for outliers but did not identify influential values.

---

**Table 1.** The demographic and clinical characteristics of the study population on the date of ECG examination ($n=55,529$).

| Characteristic | Mean ± SD or percent |
|---------------|-----------------------|
| Age in years on ECG exam date | 67 ± 7 |
| Race | White 83; Black 10; Other 7 |
| Education < college | 23 |
| BMI (kg/m²) | 29 ± 6 |
| SBP (mmHg) | 126 ± 17 |
| DBP (mmHg) | 73 ± 9 |
| Hypertension | 52 |
| Hypercholesterolemia | 20 |
| Diabetes | 8 |
| Current smoking | 6 |
| CHD* | 11 |
| Chronic lung disease | 10 |
| Beta-blocker use | 13 |
| Exam season | Spring 27; Summer 26; Fall 25; Winter 22 |
| Exam day | Monday–Thursday 86; Friday 12; Saturday–Sunday 2 |
| Exam time | Morning 64; Afternoon 36 |

*CHD includes congestive heart failure, coronary revascularization, or myocardial infarction by Minnesota Code or Novacode.

**Table 2.** The ECG parameters of the study population on the date of ECG examination ($n=55,529$).

| ECG parameter | Mean ± SD or percent |
|---------------|-----------------------|
| Minnesota codes | MC 4a 6; MC 5b 16; MC 4 or MC 5c 18 |
| T-wave amplitude ($\mu V$) | Lead I 202 ± 105; Lead II 241 ± 105; Lead AVL 86 ± 93; Lead V1 −14 ± 116; Lead V2 313 ± 197; Lead V3 349 ± 203; Lead V4 324 ± 193; Lead V5 284 ± 167; Lead V6 221 ± 120 |
| ST-segment amplitude ($\mu V$) | Lead I 13 ± 21; Lead II 19 ± 25; Lead AVL 4 ± 17; Lead V1 27 ± 27; Lead V2 64 ± 46; Lead V3 47 ± 41; Lead V4 29 ± 35; Lead V5 18 ± 29; Lead V6 11 ± 23 |

Any ST abnormality (MC 4.1–4.4); Any T abnormality (MC 5.1–5.4); Any ST–T abnormality (MC 4.1–4.4 or MC 5.1–5.4).
Initially ignoring the influences of exam site, we explored the associations between ischemia and PM$_{2.5}$ in unadjusted linear and logistic regression models. To control for residual confounding by exam season, day of week, time of day, health, and weather, we added temporal, demographic, clinical, and meteorologic characteristics to the models. We then conducted hierarchical analyses in two stages. In the first stage we used site-specific, adjusted regression models to estimate strength of the ischemia–PM$_{2.5}$ associations. The models allowed these estimates to vary among sites. In the second stage we used random effects meta-regression of the site-specific, linear regression coefficients from the first stage to estimate overall strength of the ischemia–PM$_{2.5}$ associations across sites. These weighted, iterative regression models allowed for an additive, between-study component of residual variance estimated via restricted maximum likelihood (Berkey et al. 1995). We repeated the second-stage analyses by placing uninformative priors on the second-stage parameters and Monte-Carlo sampling from the conditional distribution of each unknown using standard Bayesian hierarchical regression algorithms (Robert and Casella 2004). We evaluated effect measure modification by including cross-product terms for the interaction between PM$_{2.5}$ and CHD and its major risk factors at the first stage. Analyses based on logistic and linear regression models adjusting for exam site, and both the random-effects meta-analyses and Bayesian hierarchical regression analyses of the adjusted, site-specific regression coefficients produced similar results. We conducted all analyses using SAS version 9.1 (SAS Institute, Inc., Cary, NC) and MATLAB, version 7.0, software (MathWorks, Inc., Natick, MA). By convention, we report resulting estimates as odds ratios for ST, T abnormalities, or microvolt ($\mu$V) changes in ST-segment and T-wave amplitudes associated with 10 $\mu$g/m$^3$ increases in PM$_{2.5}$ concentrations.

Table 3. PM concentrations and weather variables for the study population on the date of ECG examination.

| Characteristic | Mean ± SD |
|----------------|-----------|
| PM$_{2.5}$     | 14.1 ± 8  |
| Lag$_{0}$      | 13.8 ± 8  |
| Lag$_{1}$      | 13.8 ± 8  |
| Lag$_{2}$      | 13.9 ± 8  |
| Lag$_{3}$      | 13.9 ± 8  |
| Lag$_{4}$      | 14.1 ± 7  |
| Weather        | 13.9 ± 7  |

Table 4. Multivariable-adjusted ORs and changes (95% CI) per 10-µg/m$^3$ increase in PM$_{2.5}$.

| ECG parameter | Lag$_{0}$ (95% CI) | Lag$_{0}$ (95% CI) |
|---------------|--------------------|--------------------|
| Minnesota Codes (OR) |                   |                    |
| MC 4          | 1.04 (0.97 to 1.10)| 1.04 (0.98 to 1.11)|
| MC 5          | 1.05 (1.00 to 1.09)| 1.04 (1.00 to 1.09)|
| MC 4 or MC 5  | 1.04 (1.00 to 1.09)| 1.03 (0.99 to 1.07)|
| Segment amplitude (µV, change) |                    |                    |
| Lead I        | –0.07 (–0.36 to 0.21)| 0.18 (–0.10 to 0.46)|
| Lead II       | –0.12 (–0.47 to 0.23)| 0.16 (–0.18 to 0.50)|
| Lead aV       | –0.01 (–0.25 to 0.23)| 0.11 (–0.12 to 0.34)|
| Lead V1       | –0.02 (–0.39 to 0.35)| 0.22 (–0.58 to 0.14)|
| Lead V2       | –0.07 (–0.57 to 0.70)| 0.01 (–0.61 to 0.62)|
| Lead V3       | –0.11 (–0.68 to 0.47)| 0.02 (–0.58 to 0.54)|
| Lead V4       | –0.03 (–0.51 to 0.45)| 0.24 (–0.23 to 0.71)|
| Lead V5       | –0.01 (–0.41 to 0.39)| 0.35 (–0.04 to 0.74)|
| Lead V6       | 0.02 (–0.30 to 0.33)| 0.35 (0.04 to 0.65)|
| T-wave amplitude (µV, change) |                    |                    |
| Lead I        | –1.60 (–3.07 to –0.13)| –0.31 (–1.73 to 1.11)|
| Lead II       | –0.54 (–1.99 to 0.92)| 0.71 (–0.70 to 2.13)|
| Lead aV       | –1.21 (–2.50 to 0.10)| –0.55 (–1.81 to 0.71)|
| Lead V1       | 1.45 (–1.16 to 3.06)| 0.03 (–1.53 to 1.59)|
| Lead V2       | –0.18 (–2.96 to 2.60)| 0.57 (–2.12 to 3.27)|
| Lead V3       | –2.33 (–5.15 to 0.49)| –0.13 (–2.87 to 2.60)|
| Lead V4       | –2.03 (–4.69 to 0.63)| 0.64 (–1.94 to 3.22)|
| Lead V5       | –1.92 (–4.22 to 0.38)| 0.56 (–1.68 to 2.78)|
| Lead V6       | –2.03 (–9.26 to 1.10)| 0.02 (–0.86 to 2.49)|

*Estimates based on logistic and linear regression models adjusted for demographic, clinical, and weather variables: age, race/ethnicity; education; exam site; BMI; current smoking status; history of CHD, diabetes, hypertension, SBP, chronic lung disease, or hypercholesterolemia; day of week; time of day; temperature; dew point; pressure and season; any ST abnormality (MC 4.1–4.4). Any T abnormality (MC 5.1–5.4). Any ST–T abnormality (MC 4.1–4.4 or MC 5.1–5.4).

Results

Of the 55,529 female participants (age range, 52–90 years), 83% were non-Hispanic white, 52% hypertensive, and 20% hypercholesterolemia (Table 1). Somewhat smaller percentages were current smokers (6%) or had diabetes (8%), CHD (11%), or chronic lung disease (10%). Six percent of the study population had ST abnormalities, and 16% had T abnormalities. Lead-specific ST and T amplitudes were normally distributed (range of means = 4, 64 µV and –14, 349 µV, respectively). Mean ± SD spatial and frontal plane QRS/T angles were 60° ± 28° and 29° ± 27°, with heart rate 66 ± 10 beats/min (Table 2). Mean PM$_{2.5}$ averaged over the first 3 days and second 3 days preceding the ECG (lag$_{0}$–2 and lag$_{0}$–3) were equivalent, as were mean temperature, dew point, and barometric pressure (Table 3).

In logistic and linear regression models adjusted for demographic, clinical, temporal, and climatic factors, 10 µg/m$^3$ increases in lag$_{0}$–2 PM$_{2.5}$ were associated with 4–5% increases in odds ratios (ORs) for ST, T, and ST–T abnormalities, small decreases in lead-specific ST and T amplitudes, and slight increases in the QRS/T angles and heart rate (Table 4). We observed decreases in T amplitude in all leads except V1, reaching a minimum of –2.3 µV [95% confidence interval (CI), –5.2 to 0.5 µV] in lead V3 even after controlling for its reported dependence on heart rate (Couderc et al. 2007). These observations were consistent across exam sites (Figure 1). The observed magnitude and direction of effects associated with lag$_{0}$–5 PM$_{2.5}$ were often weaker and less consistent [Table 4 and Supplemental Material, Tables 1 and 2 (available online at http://www.epi.ohiostate.edu/journals/09080046/suppl.pdf)]. Findings based on unadjusted models and those controlling for randomization status as well as additional participant- and contextual-level measures of education, occupation, income, and housing were comparable.

Effects of lag$_{0}$–2 PM$_{2.5}$ were slightly stronger among users versus nonusers of beta-blockers: 10% (1%, 20%) versus 3% (–1%, 8%) increases in the odds of T abnormality (p = 0.098) and –8 (–15, –1) versus 2 (–4, 1) µV decreases in T amplitude in lead V3 (p = 0.076), but in general, there was little suggestion of effect measure modification by CHD or its major risk factors.

Discussion

Judging from the U.S. EPA’s Provisional Assessment of Recent Studies on Health Effects of Particulate Matter Exposure (National Center for Environmental Assessment 2006), interest in subclinical, atherosclerotic manifestations of long-term ambient PM$_{2.5}$ exposure has dramatically increased. Indeed,
the July 2006 assessment included only one such study (of coronary artery calcium), yet in the interim, several others have also examined associations between PM$_{2.5}$ exposures sustained over months to years and noninvasive measures of atherosclerosis, including carotid intimal-medial thickness, abdominal aortic calcification, and ankle-brachial index (Allen et al. 2009; Dzie Roux et al. 2008; Hoffmann et al. 2007; Kunzli et al. 2005).

The epidemiologic associations observed in these studies are not entirely consistent with one another or collectively as strong as those that may have been anticipated on the basis of recently reported associations between chronic PM exposure and cardiovascular disease (e.g., Miller et al. 2007), and the role of atherosclerotic mechanisms in the association remains uncertain.

We examined the role of acute, ischemic mechanisms in the association between PM$_{2.5}$ and CHD among WHI clinical trial participants with this uncertainty in mind, using ECG—a simple, noninvasive, and underused research tool. In this epidemiologic context, however, we did not limit the examination to characteristics of clinically manifest ischemia (e.g., $\geq 0.1$ mV of downsloping ST segment depression and/or deep, symmetrical, precordial T-wave inversion). We opted instead to include minor abnormalities of ventricular repolarization (ST–T abnormalities, ST and T amplitudes) and depolarization (QRS/T angles) to increase sensitivity of the ECG for subclinical forms of myocardial ischemia. Using this tool, we found that a 10 $\mu$g/m$^3$ increment in lag$_{0.2}$ PM$_{2.5}$ is associated with 4–5% increased odds of minor ST, T, and ST–T abnormalities, small decreases in ST and T amplitudes across most leads and exam sites, and corresponding increases in QRS/T angles.

Previous findings from the WHI clinical trials cohort include significant prospective relationships between isolated ST–T abnormalities, lead-specific ST and T amplitudes, and wide QRS/T angle at baseline, and CHD mortality, incident CHD, and congestive heart failure (Rautaharju et al. 2006b). Similar findings also have been described in population-based settings, such as the Atherosclerosis Risk in Communities study (Zhang et al. 2007), Cardiovascular Health Study (Rautaharju et al. 2006a), and Chicago Western Electric Study (Daviglus et al. 1999), among others (Engel et al. 2004; Larsen et al. 2002; Okin et al. 2005, 2007; Schouten et al. 1992). However, the clinical utility of these ECG measures remains limited.

Considering the consistent associations between PM$_{2.5}$ and the ECG measures of myocardial ischemia observed in this context and the established, prospective association of these measures with CHD, the findings from the present study provide additional support for the hypothesis that subclinical myocardial ischemia has a pathophysiologic role in the adverse effects of acute exposure to PM$_{2.5}$ on the heart, including predisposition to ventricular arrhythmogenesis and sudden cardiac death (Rubart and Zipes 2005). This is the first study to examine such an association in a large population of postmenopausal women. Indeed, prior studies have focused on either animal models of coronary vasocostriction (Campen et al. 2005; Godleski et al. 2000; Nikolov et al. 2007; Wellenius et al. 2003) or typically small, single-city panels of CHD-burdened, Holter-monitored male participants during exercise (Gold et al. 2005; Henneberger et al. 2005; Lanki et al. 2006; Mills et al. 2007; Pekkanen et al. 2002; Yue et al. 2007) (Table 5). The findings described herein are nonetheless consistent with and thereby extend the findings previously described in these populations. They do not imply, however, that ischemia is the sole process by which PM$_{2.5}$ exerts its adverse effects on the heart. Autonomic, thrombotic, endothelial, inflammatory, oxidative, and other mechanisms of disease have all been implicated in cardiovascular effects of PM (Chuang et al. 2007; Mills et al. 2007).

This study has several limitations that may affect interpretation of its findings. First, it is an ancillary study of participants in the WHI clinical trials. Inference is therefore limited to postmenopausal women 52–90 years of age living in the contiguous 48 United States between 1999 and 2003, the initial 5-year period during which PM$_{2.5}$ data were routinely collected by the U.S. EPA AQS. Because women in the WHI clinical trials were randomized to estrogen with or without progesterin treatment,

---

**Table 5. Human studies of association of PM and ischemia.**

| Reference | No. | Location | Mean age (years) | Female (%) | Outcomes | Detection method |
|-----------|-----|----------|-----------------|------------|----------|-----------------|
| Pekkanen et al. 2002 | 45 | Helsinki, Finland | 68 | 47 | STD | E Holter |
| Henneberger et al. 2005 | 56 | Efurt, Germany | 66 | 0 | TWA | R Holter |
| Gold et al. 2005 | 24 | Boston, MA, USA | 73 | 75 | STD | E Holter |
| Lanki et al. 2006 | 45 | Helsinki, Finland | 68 | 47 | STD | E Holter |
| Yue et al. 2007 | 56 | Efurt, Germany | 66 | 0 | TWA | R Holter |
| Mills et al. 2007 | 20 | Southampton, UK | 67 | 100 | STT, STA, TWA | Resting ECG |

Abbreviations: E, exercise; R, rest; STA, ST-segment amplitude; STD, ST-segment depression; STT, ST-segment and T-wave abnormalities; TWA, T-wave amplitude. ECG involved resting, supine, standard 12-lead ECG.

*In the contiguous United States.
Allen RW, Criqui MH, Diez Roux AV, Allison MS, Shea S, Detrano R, et al. 2004. Fine particulate air pollution, proximity to traffic, and aortic atherosclerosis: the Multi-ethnic Study of Atherosclerosis. Epidemiology 2007:254–264.

Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. 1995. A random-effects regression model for meta-analysis. Stat Med 14(4):395–411.

Brook RD, Franklin SS, Vascio W, Hong YL, Howard G, Lifsett M, et al. 2004. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. Circulation 109:352–357.

Campen MJ, Babu NS, Helms GA, Pett S, Wernly J, Mehran R, et al. 2005. Nonparticipating components of diesel exhaust promotion in coronary arteries from Apoe mice. Toxicol Sci 88:136–143.

Chuang KJ, Chan CC, Su TC, Lee CT, Tang CS. 2007. The effect of urban air pollution on inflammatory oxidative, stress, coagulation, and autonomic dysfunction in young adults. Am J Resp and Crit Care Med 176:270–276.

Coudert JP, Vaglio M, Xia X, Moncti S, Wicker P, Sarapa N, et al. 2007. Impaired T-amplitude adaptation to heart rate changes affects l(II)r inhibition in the congenital and acquired forms of the long QT syndrome. ] Cardiovasc Electrophysiol 18:1299–1309.

Crooks JL, Whitel EA, Quibrera PM, Catellier DJ, Liao D, Smith RL. 2008. The effect of ignoring interpolation error on the inferred residence time between ambient particulate matter exposure and median IR interval in post-menopausal women. [Abstract]. Epidemiology 19(6):S127.

Davidgis ML, Liao Y, Greenland P, Dyer AR, Liu K, Xie X, et al. 1999. Prognosis of simple and multiple episodes of isolated nonspecific minor ST-T abnormalities. Chicago Western Electric Study. JAMA 281:530–536.

Diez Roux AV, Auchincloss AH, Franklin TG, Raghunathan T, Barr RG, Kaufman J, et al. 2008. Long-term exposure to ambient particulate matter and prevalence of subclinical atherosclerosis in the Multi-ethnic Study of Atherosclerosis. Am ] Epidemiol 167:867–875.

Dockery DW, Pope CA III, Xu X, Spengler JD, Ware JH, Fay ME, et al. 1993. An association between air pollution and mortality in six cities in the United States. N Engl ] Med 329:1753–1759.

Engel G, Beckerman JJ, Froelicher VF, Yamazaki T, Chen HA, Richardson K, et al. 2004. Electrocardiographic arrhythmia risk testing. Circulation 110:480–487.

Geddes JS, Gould DJ, van der Linden PD, O’Riordan JG, et al. 2006. Ten-year follow-up of the women’s health initiative. N Engl J Med 355:252–260.

Gold DR, Litonjua AA, Zanobetti A, Coull BA, Schwartz J, McCollum G, et al. 2005. Air pollution and ST-segment depression in elderly subjects. Environ Health Perspect 113:883–887.

Health Effects Institute. 2002. Understanding the health effects of components of the particulate matter mix: progress and next steps. HEI Perspect 2:1–20. [Available: http://pubs.healtheffects.org/getfile.php?tu=244 [accessed April 1, 2002].

Henneberger A, Zareba W, Iabal-Mulli A, Rckerl R, Curyk J, Couderc JP, et al. 2005. Repolarization changes induced by air pollution in ischemic heart disease patients. Environ Health Perspect 113:440–446.

Hoffmann B, Moebus S, Mohlenkamp S, Stang A, Lehmann N, Dragoa N, et al. 2007. Residential exposure to traffic is associated with coronary heart disease. Circulation 116:490–496.

Hui KF, Castellanos A, Myerburg RJ. 2001. Sudden death due to cardiac arrhythmias. N Engl ] Med 345(20):1473–1482.

Ikko T, Thurston GD, Nadas A, Lippmann M. 2001. Monitor-to-monitor temporal correlation of air pollution and weather variables in the North-Central U.S. ] Expo Anal Environ Epidemiol 11(1):21–32.

Künzi N, Jerrett M, Mack WJ, Beckerman B, LaBree L, Gilliland F, et al. 2005. Ambient air pollution and atherosclerosis in Los Angeles. Environ Health Perspect 113:201–206.

Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Truesdell M. 2003. The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13(6):517–521.

Lanki T, de Hartog JJ, Heinrich J, Hoek G, Janssen NA, Peters A, et al. 2006. Can we identify sources of fine particles responsible for exercise-induced ischemia on days with elevated air pollution? The ULTRA study. Environ Health Perspect 114:655–660.

Larsen CT, Dahlín J, Blackburn H, Scharling H, Appleyard M, Sigurd B, et al. 2002. Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave: the Copenhagen City Heart Study. Eur Heart ] 2002;34(4):315–324.

Liao D, Pepeuet DJ, Duan Y, Whitel EA, Dou J, Smith RL, et al. 2006. GIS approaches for the estimation of residential-level ambient PM concentrations. Environ Health Perspect 2006;114:1374–1380.

Liao D, Pepeuet DJ, Lin H, Duan Y, Whitel EA, Smith RL, et al. 2007. National nongressive ischemia estimation. Environ Health Perspect 115:A33B–A339.

Miller KA, Siscovick DS, Shepherd L, Shepherd K, Sullivan JH, Anderson G, et al. 2007. Long-term exposure to air pollution and incidence of cardiovascular events in women. ] Engl J Med 356:447–458.

Mills NL, Tornqvist H, Gonzalez MC, Vink E, Robinson SD, Soderberg S, et al. 2007. Ischemic and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary heart disease. N Engl ] Med 357:1075–1082.

National Research Council. 2004. Research Priorities for Airborne Particulate Matter: IV. Continuing Research Progress. Washington, DC:National Academies Press.

Nikolov MC, Coull BA, Catalan J, Godleski J. 2007. An informative Bayesian structural equation model to assess source-specific health effects of air pollution. Biostatistics 8(3):619–624.

Okin PM, Roman MJ, Best LG, Lee ET, Galloway Howard BV, et al. 2005. Cross-reactive protein and electrocardiographic ST-segment depression additively predict mortality: the Strong Heart Study. ] Am Coll Cardiol 45(11):1787–1793.

Okin PM, Roman MJ, Lee ET, Galloway Howard BV, et al. 2007. Usefulness of quantitative assessment of electrocardiographic ST depression for predicting new-onset heart failure in American Indians (from the Strong Heart Study). Am ] Cardiol 100(1):94–98.

Panes J, Peters A, Hoek G, Tijssen JG, Brunekeef B, de Hartog J, et al. 2002. Particulate air pollution and risk of ST-segment depression during repeated submaximal exercise tests among subjects with coronary heart disease: the Exposure and Risk Assessment for Fine and Ultrafine Particles in Ambient Air (ULTRA) study. Circulation 106(6):933–938.

Pea CO III, Mullerstein JB, Mary HT, Renlund DG, Anderson JL, Horne BD. 2008. Ischemic heart disease event triggered by short-term exposure to fine particulate air pollution. Health Care Effectiveness Research Priorities for Cardiovascular Disease. 2007:155–159.

Rauhut PM, Ge S, Nelson J, Marino Larsen EK, Peaty BM, Furberg CD, et al. 2006a. Comparison of mortality risk for electrocardiographic abnormalities in men and women and within coronary heart disease (from the Cardiovascular Health Study). Am ] Cardiol 97(9):859–860.

Rauhut PM, Kooperberg C, Larson JC, LaCroix A. 2006b. Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women. The Women’s Health Initiative. Circulation 113:473–480.

Robert CP, Casella G. 2004. Monte Carlo Statistical Methods. 2nd ed. New York:Springer-Verlag.
Rubart M, Zipes DP. 2005. Mechanisms of sudden cardiac death. J Clin Invest 115:2305–2315.
Schouten EG, Dekker JM, Pool J, Kok FJ, Simoons ML. 1992. Well shaped ST segment and risk of cardiovascular mortality. BMJ 304(6823):356–359.
Sapiro AA, Sheppard L, Sampson PD, Kim SY. 2007. Validating national kriging exposure estimation [Letter]. Environ Health Perspect 115:A338.
U.S. EPA (Environmental Protection Agency). 2008a. Air Trends. National Trends in Particulate Matter Levels. Available: http://www.epa.gov/airtrends/pm.html [accessed 4 September 2008].
U.S. EPA (Environmental Protection Agency). 2008b. Air and Radiation. National Ambient Air Quality Standards. Available: http://www.epa.gov/air/criteria.html [accessed 28 March 2008].
U.S. EPA (Environmental Protection Agency). 2006. Provisional Assessment of Recent Studies on Health Effects of Particulate Matter Exposure. Available: http://www.epa.gov/particles/pdfs/ord_report_20060720.pdf [accessed 1 July 2006].
U.S. National Climatic Data Center. 2007. Global Surface Hourly Data, 2007. Available: http://hurricane.ncdc.noaa.gov/pils/plclimprod/poemain.accessrouter?dasettbl=DS3505 [accessed 29 March 2007].
Wellenius GA, Coull BA, Godleski JJ, Koutrakis P, Okabe K, Savage ST, et al. 2003. Inhalation of concentrated ambient air particles exacerbates myocardial ischemia in conscious dogs. Environ Health Perspect 111:402–408.
Whitsel EA, Quibrera PM, Smith RL, Catellier DJ, Liao D, Henley AC, et al. 2006. Accuracy of commercial geocoding: assessment and implications. Epidemiol Perspect Innov 3(1): doi: 10.1186/1742-5573-3-8 [Online 20 July 2006].
WHI (Women’s Health Initiative) Study Group. 1998. Design paper: design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 19:61–109.
Yue W, Schneider A, Stößel M, Rückerl R, Cyris J, Pan X, et al. 2007. Ambient source-specific particles are associated with prolonged repolarization and increased levels of inflammation in male coronary artery disease patients. Mutat Res 621(1–2):50–60.
Zareba W, Nomura A, Couderc JP. 2001. Cardiovascular effects of air pollution: what to measure in ECG? Environ Health Perspect 109(suppl 4):533–538.
Zhang ZM, Prineas RJ, Case D, Soliman EZ, Rautaharju PM, ARIC Research Group. 2007. Comparison of the prognostic significance of the electrocardiographic QRS/T angles in predicting incident coronary heart disease and total mortality [from the Atherosclerosis Risk in Communities study]. Am J Cardiol 100(6):844–849.
Zhang ZM, Whitsel EA, Smith RL, Quibrera PM, Liao D, Anderson GL, et al. 2008. Ambient particulate matter air pollution (PM) and myocardial ischemia: the Environmental Epidemiology of Arrhythmogenesis in the Women’s Health Initiative (EEAWHI) [Abstract]. Circulation 117(11):e253; doi:10.1161/CIRCULATIONAHA.107.189344.